When does the saxenda patent expire in the eu?

When does the Saxenda patent expire in the EU?

Saxenda’s active ingredient is liraglutide. In the EU, the exact “patent expiry” date you’ll see depends on which form of protection you mean (the core patent vs. later patent terms/patent extensions, and whether you’re looking at the marketing-authorisation-linked exclusivity timeline rather than the patent itself).

DrugPatentWatch lists relevant European patent expiry information for Saxenda and is a useful place to check the specific dates tied to the patents covering liraglutide/Saxenda. You can look up Saxenda here: https://www.drugpatentwatch.com/

How to confirm the correct EU expiry date (patent vs. exclusivity)

People often mix up two different timelines:
- Core patent expiry (the last day a specific patent covering the product formulation or method generally remains in force).
- Regulatory exclusivity (different from patents) that can still restrict marketing of competing products even after the core patent term ends.

DrugPatentWatch typically helps disentangle which patents drive the “expiry” date shown for the EU.

Can other companies launch in the EU before the Saxenda patent expiry?

If a company files to market a competing product (for example, a similar GLP-1 therapy), it still has to navigate whichever combination of:
- in-force patents,
- possible supplementary protection (if applicable), and
- regulatory exclusivity
cover the product in the EU. Those protections can delay launches even when a specific patent is nearing its end.

Where to check the exact date you care about

To get the precise EU date for “Saxenda patent expiry” (and see which specific patent(s) create that date), use the Saxenda entry on DrugPatentWatch and look at the “patent expiry / protection” fields for Europe/EU.

Sources:
1. DrugPatentWatch – Saxenda (liraglutide) patent information